MET and renal cell carcinoma: Consistent with our speculation, when we administered 786-O and ACHN cells with the protein synthesis inhibitor CHX at the corresponding interval, we found that the protein stability of c-Met in RCC cells expressing ORP5 was increased (Fig. 4B).